<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02220296</url>
  </required_header>
  <id_info>
    <org_study_id>NN1438-4137</org_study_id>
    <secondary_id>2014-000071-70</secondary_id>
    <secondary_id>U1111-1151-9327</secondary_id>
    <nct_id>NCT02220296</nct_id>
  </id_info>
  <brief_title>A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The purpose is to evaluate safety and tolerability of a
      range of single doses of subcutaneous insulin 338.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2014</start_date>
  <completion_date type="Actual">March 31, 2015</completion_date>
  <primary_completion_date type="Actual">March 31, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Day 1 - day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycaemic episodes</measure>
    <time_frame>Day 1 - day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin 338 concentration-time curve from zero to infinity</measure>
    <time_frame>Day 1- day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum insulin 338 concentration observed</measure>
    <time_frame>Day 1- day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for maximum serum insulin 338 concentration</measure>
    <time_frame>Day 1- day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2, the terminal half-life of insulin 338</measure>
    <time_frame>Day 1- day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Healthy</condition>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Part 1 insulin 338</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 insulin 338</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 insulin glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin 338</intervention_name>
    <description>Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).</description>
    <arm_group_label>Part 1 insulin 338</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).</description>
    <arm_group_label>Part 1 placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin 338</intervention_name>
    <description>Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).</description>
    <arm_group_label>Part 2 insulin 338</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).</description>
    <arm_group_label>Part 2 insulin glargine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Trial Part 1 (Healthy subjects):

          -  Male subject

          -  Age 18-55 (both inclusive) at the time of signing inform consent

          -  Body mass index 19.0-29.9 kg/m^2 (both inclusive)

          -  Trial Part 2 (Subjects with type 1 diabetes mellitus):

          -  Male subject or female subject of non-child bearing potential. Non-child bearing
             potential: being surgically sterilized (i.e. tubal ligation, bilateral oopherectomies
             or hysterectomised) for more than 3 months or being postmenopausal (as defined by
             amenorrhoea for at least 2 years prior to screening and documented by
             follicle-stimulating hormone (FSH) 40 U/L)

          -  Age 18-64 years (both inclusive) at the time of signing inform consent

          -  Body mass index 19.0-29.9 kg/m^2 (both inclusive)

          -  Type 1 diabetes mellitus (as diagnosed clinically) for 12 months or longer

          -  Treated with multiple daily insulin injections or insulin pump treatment for 12 months
             or longer

          -  Glycated hemoglobin (HbA1c) 9.0% or less

          -  Fasting C-peptide less than 0.3 nmol/L

        Exclusion Criteria:

          -  Trial Part 1 (healthy subjects):

          -  History of, or presence of, cancer, diabetes mellitus or any clinically significant
             cardiovascular, respiratory, metabolic (including dyslipidemia), renal, hepatic,
             gastrointestinal, endocrinological, haematological, dermatological, venereal,
             neurological, psychiatric diseases or other major disorders, as judged by the
             investigator

          -  Increased risk of thrombosis, e.g. subjects with a history of deep leg vein thrombosis
             or family history of deep leg vein thrombosis, as judged by the investigator

          -  Currently smoke more than 1 cigarette per day (or the equivalent for other tobacco
             products) or smoking 1 cigarette or less per day and not considering being able to
             refrain from smoking or refrain from use of other types of nicotine products (e.g.
             such as chewing tobacco, nicotine gums) during the in-house periods

          -  Trial Part 2 (subjects with type 1 diabetes mellitus):

          -  History of, or presence of, cancer or any clinically significant respiratory,
             metabolic, renal, hepatic, gastrointestinal, endocrinological (with the exception of
             conditions associated with diabetes mellitus), haematological, dermatological,
             venereal, neurological, psychiatric, other major disorders or personal and/or family
             history of thromboembolism, as judged by the investigator

          -  Increased risk of thrombosis, e.g. subjects with a history of deep leg vein thrombosis
             or family history of deep leg vein thrombosis, as judged by the investigator

          -  Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last
             12 months) or hypoglycaemic unawareness as judged by the Investigator or
             hospitalisation for diabetic ketoacidosis during the past 6 months before start of
             this trial (screening)

          -  Cardiac problems defined as: 1) decompensated heart failure (New York Heart
             Association (NYHA) class III and IV) at any time, or 2) acute myocardial infarction at
             any time, or 3) angina pectoris within the last 12 months before start of this trial
             (screening)

          -  Currently smoke more than 1 cigarette per day (or the equivalent for other tobacco
             products) or smoking 1 cigarette or less per day and not considering being able to
             refrain from smoking or refrain from use of other types of nicotine products (e.g.
             such as chewing tobacco, nicotine gums) during the in-house periods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2014</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

